Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (TSE:FRX)
TSX:FRX
FRX Stock Chart & Stats
C$10.18
C$0.03(0.34%)
At close: 4:00 PM EST
C$10.18
C$0.03(0.34%)
Day’s Range― - ―
52-Week RangeC$7.02 - C$13.83
Previous CloseN/A
Volume1.30K
Average Volume (3M)377.00
Market Cap
$356.59M
Enterprise ValueC$201.13M
Total Cash (Recent Filing)$21.93M
Total Debt (Recent Filing)$18.09M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 24, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding34,139,973
10 Day Avg. Volume146
30 Day Avg. Volume377
Financial Highlights & Ratios
PEG Ratio3.19
Price to Book (P/B)-22.88
Price to Sales (P/S)2.83
P/FCF Ratio4.98
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue5.19
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda-54.23
Forecast
1Y Price Target
$20.56Price Target Upside101.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.91
Revenue Forecast (FY)$108.23M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And ProfitabilityRedemption of all outstanding debt and a strengthened balance sheet could support sustained profitability and higher operating margins, especially given a lean commercial model.
Real-world EvidenceA major cancer institute-led real-world study evaluating PEDMARK's ability to reduce hearing damage in older patients could strengthen clinical support for wider use and inform future regulatory or guideline updates.
Regulatory ExpansionPlans to pursue regulatory approval and potential licensing or partnership arrangements in Japan could open a significant new market for PEDMARK and increase global revenue opportunities.
Bears Say
Intellectual Property RiskPotential challenges to intellectual property protection or competitive entries could erode exclusivity and place pressure on future sales and pricing power.
Partnership UncertaintyUncertainties or delays in securing partnerships or licensing agreements for commercialization in additional territories could limit market expansion plans and slow international sales momentum.
U.S. Commercial Uptake RiskSlower-than-expected adoption of PEDMARK in the United States could weaken revenue growth and delay the company reaching or sustaining profitability.
Fennec Pharmaceuticals News
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.02 and its highest was C$13.83 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $356.59M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Mar 24, 2026 which is in 5 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -C$0.028 earnings per share for the quarter, beating the consensus estimate of -C$0.031 by C$0.003.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,139,973 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -C$0.028 in its last earnings report, beating expectations of -C$0.031. Following the earnings report the stock price went down -1.109%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.56 (101.95% Upside)
$20.56 (101.95% Upside)
Blogger Sentiment
Bullish
TSE:FRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.78%
12-Months-Change
Fundamentals
Return on Equity
117.12%
Trailing 12-Months
Asset Growth
-16.39%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FRX Stock 12 Month Forecast
Average Price Target
C$20.56
▲(101.95% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
NervGen Pharma
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Options Prices
Currently, No data available
---